This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The report shows that investment in HIV prevention research fell 4 percent in 2013, due to a combination of factors including declining investments by the United States and European donors, changes in the international development landscape and changes in the pipeline of HIV prevention products being tested.
HIV Prevention Research & Development Investment in 2013: In a changing global development, economic and human rights landscape
When do you stop an HIV prevention trial for futility? A primer for HIV prevention advocates
This fact sheet looks at why trials are stopped early for “futility.” What does this mean, when is such a recommendation made and how does it affect other ongoing trials?
Jeff McConnell Memorial Webinar – Audio
This webinar memorialized pioneering sociologist Jeff McConnell and his impact on HIV prevention science. Updates were presented on pre-exposure prophylaxis (PrEP) research and the implications of Dr. McConnell’s research on sexual networks for how PrEP will be implemented.Find details, slides and full flash webinar here.
HIV Prevention Europe Webinars: Rectal microbicides
The seventh webinar in our series addressing a range of topics in HIV prevention research, hosted jointly by NAM and AVAC, focused on rectal microbicides. Speakers included: Ian McGowan, University of Pittsburgh; Carolina Herrera, Imperial College; Alex Carballo-Dieguez, Columbia University; and Marc-André LeBlanc, IRMA.
The presentation was followed by a Q&A session. Click here for slides and audio from the webinar.
Will a pill a day prevent HIV? Anticipating the results of the tenofovir “PrEP” trials
This 2005 report examines the issues surrounding the tenofovir trials and makes recommendations for ensuring that trials are carried out ethically and that provisions are made for dealing with the results of the trials when they are available. The report also calls for more concerted coordination and advance planning to accelerate evaluation, licensing, and access to PrEP.
Understanding the Results of the AIDSVAX Trial
In late February 2003, the world heard preliminary results of the first large-scale human trial of a vaccine designed to prevent HIV infection. The results for the overall trial cohort were clear and disappointing. The results for a relatively small subset of trial participants are less clear, and they have sparked controversy and require further analysis. This brochure will help you understand what we do and do not know about the experimental vaccine known as AIDSVAX.
Understanding the Results of the AIDSVAX Trial (French)
In late February 2003, the world heard preliminary results of the first large-scale human trial of a vaccine designed to prevent HIV infection. The results for the overall trial cohort were clear and disappointing. The results for a relatively small subset of trial participants are less clear, and they have sparked controversy and require further analysis. This brochure will help you understand what we do and do not know about the experimental vaccine known as AIDSVAX.
Understanding the Results of the AIDSVAX Trial (Spanish)
In late February 2003, the world heard preliminary results of the first large-scale human trial of a vaccine designed to prevent HIV infection. The results for the overall trial cohort were clear and disappointing. The results for a relatively small subset of trial participants are less clear, and they have sparked controversy and require further analysis. This brochure will help you understand what we do and do not know about the experimental vaccine known as AIDSVAX.
Antiretroviral Treatment for Prevention of HIV and Tuberculosis
Despite considerable evidence supporting the use of antiretroviral therapy (ART) for prevention of HIV and TB illness, death and transmission, only 37 percent of the 35 million people living with HIV were receiving it in 2013. This paper examines ongoing and planned global treatment as prevention studies and addresses research questions related to access and implementation.
Facing Questions about Hormonal Contraceptives and HIV: What’s next in getting answers?
In this webinar we learned about and discussed proposed research to directly evaluate how different family planning methods might impact HIV risk.
Trial designs are actively being discussed and funding is being sought for such research—but there are many questions where advocates’ voices are needed: What should a trial look like? How can method mix (the range of available family planning options) be expanded for all women? What can be done to better integrate HIV and family planning in the meantime?
View the full webinar here